scholarly article | Q13442814 |
P50 | author | Paola Ulivi | Q39596199 |
Oriana Nanni | Q43073188 | ||
P2093 | author name string | W Zoli | |
R Silvestrini | |||
G L Frassineti | |||
E Pasquini | |||
M Ballardini | |||
R Gunelli | |||
M Fiori | |||
G L Pappagallo | |||
N Giovannini | |||
E Bercovich | |||
P2860 | cites work | A phase I clinical, plasma, and cellular pharmacology study of gemcitabine | Q28334915 |
New colorimetric cytotoxicity assay for anticancer-drug screening | Q29615418 | ||
Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder. | Q33343442 | ||
Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study | Q33365072 | ||
A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer | Q33504597 | ||
Improved patient outcomes with BCG immunotherapy vs. chemotherapy - Swedish and worldwide experience | Q33781017 | ||
In vitro preclinical models for a rational design of chemotherapy combinations in human tumors | Q34133637 | ||
Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study | Q40496147 | ||
Schedule-dependent cytotoxic interaction between epidoxorubicin and gemcitabine in human bladder cancer cells in vitro | Q40587184 | ||
The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee | Q40831782 | ||
In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems | Q41055471 | ||
Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study | Q44315406 | ||
Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation. | Q44791621 | ||
Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC). | Q45014818 | ||
In vitro pharmacodynamics of 1-beta-D-arabinofuranosylcytosine: synergy of antitumor activity with cis-diamminedichloroplatinum(II). | Q46082232 | ||
Optimal two-stage designs for phase II clinical trials | Q46412217 | ||
Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer | Q46610841 | ||
Intravesical gemcitabine in recurrent superficial bladder carcinoma: preliminary results on ablative efficacy and tolerability. | Q46634674 | ||
Treatment of Bacillus Calmette-Guerin refractory superficial bladder cancer: further intravesical therapy | Q46704520 | ||
Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder. | Q53617199 | ||
Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials | Q64112022 | ||
Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs | Q73025541 | ||
5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group | Q74614253 | ||
P433 | issue | 11 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | bladder cancer | Q504775 |
P1104 | number of pages | 6 | |
P304 | page(s) | 1499-1504 | |
P577 | publication date | 2007-11-06 | |
P1433 | published in | British Journal of Cancer | Q326309 |
P1476 | title | Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study | |
P478 | volume | 97 |
Q39634997 | Enhanced antitumor effect of coincident intravesical gemcitabine plus BCG therapy in an orthotopic bladder cancer model |
Q39315907 | Everolimus enhances gemcitabine-induced cytotoxicity in bladder-cancer cell lines. |
Q43159409 | Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial |
Q41434863 | Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer |
Q37982150 | Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review |
Q38063552 | Intravesical therapies for bladder cancer - indications and limitations. |
Q37053724 | Novel Simulation Model of Non-Muscle Invasive Bladder Cancer: A Platform for a Virtual Randomized Trial of Conservative Therapy vs. Cystectomy in BCG Refractory Patients. |
Q84060912 | Phase II study of biweekly gemcitabine as first line therapy in CIS of the bladder: what does an aborted trial tell us? |
Q33962426 | SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin |
Q82497871 | Second-Line Intravesical Gemcitabine in High Risk Superficial Bladder Cancer: Our Experience |
Q90116225 | Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin |
Search more.